tbuckley/cabot-search huggingface dataset:
Identifying the Intergenic <i>ALK</i> Fusion <i>LOC388942‐ALK</i> as a Driver of Non–Small Cell Lung Cancer
Authors: Xiaoqian Zhai, Manli Wang, Qi Zhang, Donglin Li, Yanmou Wu, ZuoYu Liang, Jiewei Liu, Weiya Wang, Yu Liu, Guowei Che, Qinghua Zhou, Chong Chen
Journal: MedComm (2025)

ABSTRACT ALK fusions, such as the classic EML4‐ALK , are known drivers of lung cancer and effective therapeutic targets. However, variant ALK fusions, including intergenic fusions like LOC388942‐ALK ( LA ), have been detected in increasing numbers of patients, with their roles in tumorigenesis and ALK inhibitor resistance remaining unclear. Using CRISPR/Cas9, we generated the LA fusion in A549 and H441 cells, confirming elevated ALK expression via qRT‐PCR and immunohistochemistry (IHC) staining. Functional analyses showed that LA significantly promoted tumor growth in vitro and in vivo while conferring increased resistance to alectinib. RNA‐seq revealed upregulation of the FOS pathway in LA tumors, identifying FOS as a potential therapeutic target. Subsequently, we demonstrated that FOS disruption and inhibition sensitized LA tumors to treatment. RNA‐seq profiling demonstrated that FOS depletion in LOC388942‐ALK tumor significantly downregulated multiple oncogenic pathways related to cell cycle progression, DNA replication fidelity, and extracellular matrix remodeling, suggesting a pivotal role of FOS in maintaining tumor growth. These findings establish LOC388942‐ALK as a novel oncogenic driver in lung cancer, highlighting its role in tumor growth and ALK inhibitor resistance. Targeting FOS may provide a promising therapeutic strategy for tumors harboring this intergenic fusion.
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
Authors: Vinod Pullarkat, Keith W. Pratz, Hartmut Döhner, Christian Recher, Michael J. Thirman, Courtney D. DiNardo, Pierre Fenaux, Andre C. Schuh, Andrew H. Wei, Arnaud Pigneux, Jun-Ho Jang, Gunnar Juliusson, Yasushi Miyazaki, Dominik Selleslag, Martha L. Arellano, Chenglong Liu, Jean A. Ridgeway, Jalaja Potluri, Jovita Schuler, Marina Konopleva
Journal: Blood Cancer Journal (2025)
DEVELOPMENT OF A CLINICAL PREDICTION TOOL TO PREDICT POSTOPERATIVE ATRIAL FIBRILLATION FOLLOWING MAJOR THORACIC SURGERY
Authors: El Hadji Diallo, Philippe Brouillard, Zakaria Ratemi, Victoria Di Quinzio, Jean-Marc Raymond, Moishe Liberman, Emmanuelle Duceppe, Brian J. Potter
Journal: Journal of the American College of Cardiology (2025)
EFFICACY OF BOTULINUM TOXIN IN PREVENTING ATRIAL FIBRILLATION IN POST-CARDIOVASCULAR SURGERY PATIENTS: A META-ANALYSIS
Authors: Luis Enrique Cueva Cañola, Yoshua Flores, Adolfo Calderón-Fernández, Camile Viruez Nogueira, Bruno Viruez Nogueira, Karoly Pamela Zuñiga Montaño, Luis Alberto Rojas Trejo, Erick Calvario
Journal: Journal of the American College of Cardiology (2025)
LONG TERM OUTCOMES WITH CLASS 1C ANTI-ARRHYTHMIC DRUG USE IN ATRIAL FIBRILLATION
Authors: Aditya Bhonsale, Yisi Wang, Floyd Thoma, KRISHNA KANCHARLA, Andrew H. Voigt, Alaa A. Shalaby, Virginia Singla, Aditi Naniwadekar, Nathan Anthony Estes, Samir F. Saba, Suresh Mulukutla, Sandeep K. Jain
Journal: Journal of the American College of Cardiology (2025)
PATTERNS OF POST-ABLATION RECURRENCE AND ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION
Authors: Sitong Li, Jingrui Zhang, Chao Jiang, Liu He, Ning Zhou, Caihua Sang, DE YONG LONG, Xin Du, Jianzeng Dong, Changsheng Ma
Journal: Journal of the American College of Cardiology (2025)
THE IMPACT OF ATRIAL FIBRILLATION ON IN-HOSPITAL OUTCOMES IN PATIENTS UNDERGOINGLIVER TRANSPLANTATION USING NIS 2016-2021
Authors: Omar Sami Abdelhai, Ratib Mahfouz, Anand Maligireddy, Gautam Rangavajla, Tyler Q. Andrews, Ahmad Jabri, Muhammad Memon, Patrick McBride, Pedro Arturo Villablanca, Dawood Jamil, Vikas Aggarwal
Journal: Journal of the American College of Cardiology (2025)
Dynamic <sup>11</sup>C-PABA PET/CT for Visualizing Pulmonary <i>Mycobacteroides abscessus</i> Infections
Authors: Yuderleys Masias-Leon, Carlos E. Ruiz-Gonzalez, Oscar J. Nino-Meza, Medha Singh, Mona O. Sarhan, Xueyi Chen, Kelly Flavahan, Amy Kronenberg, Elizabeth W. Tucker, Joel S. Freundlich, Martin A. Lodge, Laurence S. Carroll, Nicole Parrish, Noah Lechtzin, Sanjay K Jain
Journal: American Journal of Respiratory and Critical Care Medicine (2025)

Rationale: Mycobacteroides abscessus infections affect immunocompromised patients and those with underlying pulmonary disease. Conventional imaging cannot distinguish M. abscessus infections from underlying pulmonary disease or sterile inflammation, requiring invasive procedures for definitive diagnosis. Objective: We evaluated 11C-para-aminobenzoic acid (11C-PABA), a chemically identical radioanalog of PABA, to detect and localize infections due to M. abscessus. Methods: In vitro uptake assays were performed to test the metabolism and accumulation of PABA into M. abscessus reference and clinical isolates. Dynamic 11C-PABA positron emission tomography (PET) was performed in a mouse model of M. abscessus pulmonary infection and in a patient with microbiologically-confirmed M. abscessus pulmonary infection (NCT05611905). Main Results: 11C-PABA was intracellularly metabolized by M. abscessus to 11C-7,8-dihydropteroate. Additionally, and the reference and all thirteen randomly chosen clinical isolates, including three resistant to trimethoprim-sulfamethoxazole, rapidly accumulated PABA. No PABA accumulation was noted by heat-inactivated bacteria or mammalian cells. Dynamic 11C-PABA PET in a mouse model of M. abscessus pulmonary infection rapidly distinguished infection from sterile inflammation and also accurately monitored response to antibiotic treatment. Finally, dynamic 11C-PABA PET in a 33-year-old female with cystic fibrosis and microbiologically confirmed M. abscessus pulmonary infection was safe and demonstrated significantly higher and sustained PET uptake in the affected lesions. Conclusions: 11C-PABA PET is an innovative, clinically-translatable, noninvasive, bacteria-specific diagnostic to differentiate M. abscessus infections from underlying pulmonary disease in patients. This tool could also help in monitoring treatment responses and enable precision medicine approaches for patients with complicated infections. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).
REMOTE ISCHEMIC PRECONDITIONING PROMISES CARDIOPROTECTIVE AND ANTI-ARRYTHMIC EFFECTS IN THE TREATMENT OF ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW OF CLINICAL TRIALS
Authors: Tehreem Fatima, Rukshar Thapa, Silla Naeem, Tahira Irshad, Sheraz Ali, Mahnoor Usman, Ayesha Sehar, Qasim Mehmood, Muhammad Nabeel Saddique, Faiza Fatima, Pakeeza Saif Saif Ullah, Uzair Iqbal, Zobia Farooq
Journal: Journal of the American College of Cardiology (2025)
REVOLUTIONIZING ABLATION TECHNIQUES: A META-ANALYSIS OF PULSED FIELD ABLATION VS RADIOFREQUENCY ABLATION AND CRYOABLATION
Authors: Poojan Jayesh Prajapati, Juan F. Rodriguez-Riascos, Padmapriya Muthu, Hema Vemulapalli, Komandoor S. Srivathsan
Journal: Journal of the American College of Cardiology (2025)
ORAL ANTICOAGULATION AFTER PULSED-FIELD ABLATION FOR ATRIAL FIBRILLATION
Authors: Sanghamitra Mohanty, Paolo Compagnucci, Vincenzo Mirco La Fazia, Carola Gianni, Bryan MacDonald, angel mayedo, John Allison, G.J. Gallinghouse, John D. Burkhardt, Rodney P. Horton, Amin Al-Ahmad, Luigi Di Biase, Michela Casella, Antonio Dello Russo, Andrea Natale
Journal: Journal of the American College of Cardiology (2025)
IN-HOSPITAL AND ONE-YEAR OUTCOMES AFTER LEFT ATRIAL APPENDAGE OCCLUSION FOR PATIENTS WITH REDUCED EJECTION FRACTION
Authors: Angela Higgins, Chien-Yu Huang, Sarah Zimmerman, Amit N. Vora, Daniel J. Friedman, Kamil Faridi, Richa Sharma, Jeptha P. Curtis, James V. Freeman
Journal: Journal of the American College of Cardiology (2025)
EXERCISE TOLERANCE AND QUALITY OF LIFE IN ATRIAL FIBRILLATION PATIENTS WITH OR WITHOUT LEFT ATRIAL APPENDAGE ISOLATION
Authors: Sanghamitra Mohanty, Prasant Mohanty, Vincenzo Mirco La Fazia, Carola Gianni, Bryan MacDonald, Angel Mayedo, Amin AlAhmad, John D. Burkhardt, G. Joseph Gallinghouse, Rodney P. Horton, Andrea Natale
Journal: Journal of the American College of Cardiology (2025)
WATCHFUL WAITING FOR FREQUENT MINIMALLY SYMPTOMATIC PVCS
Authors: Mohammed B. Naji, Christopher Scoma, Troy M. LaBounty, Michael Ghannam, Jackson J. Liang, Amrish Deshmukh, Kelly Arps, Rakesh Latchamsetty, Krit Jongnarangsin, Fred Morady, Frank M. Bogun
Journal: Journal of the American College of Cardiology (2025)
NON-ABLATION MANAGEMENT OF FREQUENT PREMATURE VENTRICULAR COMPLEXES IN PATIENTS REFERRED FOR ABLATION
Authors: Mohammed B. Naji, Christopher Scoma, Troy M. LaBounty, Michael Ghannam, Jackson J. Liang, Amrish Deshmukh, Kelly Arps, Rakesh Latchamsetty, Krit Jongnarangsin, Fred Morady, Frank M. Bogun
Journal: Journal of the American College of Cardiology (2025)
VENTRICULAR TACHYCARDIA CATHETER ABLATION IN PATIENTS WITH CARDIAC AMYLOIDOSIS; A COMPARISON TO VT ABLATION IN GENERAL POPULATION
Authors: Khaled Alabdallah, Iad Alhallak, Jimmy Hong, Ritika Saxena, Wissam Khalife, Haider Al Taii
Journal: Journal of the American College of Cardiology (2025)
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez, Claire Grange, Manuel Monreal, Juan J López-Núñez, Remedios Otero-Candelera, Grégoire Le Gal, Erik Yeo, Marc Righini, Helia Robert-Ebadi, Menno V Huisman, Frederikus A Klok, Peter Westerweel, Giancarlo Agnelli, Cecilia Becattini, Aristotelis Bamias, Kostas Syrigos, Sebastian Szmit, Adam Torbicki, Peter Verhamme, Anthony Maraveyas, Alexander T Cohen, Cihan Ay, Céline Chapelle, Guy Meyer, Francis Couturaud, Patrick Mismetti, Philippe Girard, Laurent Bertoletti, Silvy Laporte
Journal: New England Journal of Medicine (2025)

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and decreasing bleeding is unclear. We conducted a randomized, double-blind, noninferiority trial with blinded central outcome adjudication. Consecutive patients with active cancer and proximal deep-vein thrombosis or pulmonary embolism who had completed at least 6 months of anticoagulant therapy were randomly assigned in a 1:1 ratio to receive oral apixaban at a reduced (2.5 mg) or full (5.0 mg) dose twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal recurrent venous thromboembolism, assessed in a noninferiority analysis (margin of 2.00 for the upper boundary of the 95% confidence interval of the subhazard ratio). The key secondary outcome was clinically relevant bleeding, assessed in a superiority analysis. A total of 1766 patients underwent randomization at a median time since the index event of 8.0 months (interquartile range, 6.5 to 12.6); 866 patients were assigned to the reduced-dose group, and 900 to the full-dose group. The median treatment duration was 11.8 months (interquartile range, 8.3 to 12.1). Recurrent venous thromboembolism occurred in 18 patients (cumulative incidence, 2.1%) in the reduced-dose group and in 24 (cumulative incidence, 2.8%) in the full-dose group (adjusted subhazard ratio, 0.76; 95% confidence interval [CI], 0.41 to 1.41; P = 0.001 for noninferiority). Clinically relevant bleeding occurred in 102 patients (cumulative incidence, 12.1%) in the reduced-dose group and in 136 (cumulative incidence, 15.6%) in the full-dose group (adjusted subhazard ratio, 0.75; 95% CI, 0.58 to 0.97; P = 0.03). Mortality was 17.7% in the reduced-dose group and 19.6% in the full-dose group (adjusted hazard ratio, 0.96; 95% CI, 0.86 to 1.06). Extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for the prevention of recurrent venous thromboembolism in patients with active cancer. The reduced dose led to a lower incidence of clinically relevant bleeding complications than the full dose. (Funded by the Bristol-Myers Squibb-Pfizer Alliance; API-CAT ClinicalTrials.gov number, NCT03692065.).
SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ARE ASSOCIATED WITH A LOWER RISK OF ATRIAL FIBRILLATION COMPARED TO GLUCAGON-LIKE PEPTIDE-1 AGONISTS: A DIRECT METAANALYSIS
Authors: George G. Kidess, Mohammad Hamza, Mowaffak Alraiyes, Farah Yasmin, Jawad Basit, M. Chadi Alraies
Journal: Journal of the American College of Cardiology (2025)
ACTIVE COMPRESSION DURING CARDIOVERSION FOR ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Abdalhakim Shubietah, Hosam I. Taha, Hazem R. Mansour, Sherif Sary, Ahmed A. Ibrahim, Abubakar Nazir, Mohamed S. Elgendy, Mohamed Abuelazm
Journal: Journal of the American College of Cardiology (2025)
INFLUENCE OF HIGH-FREQUENCY LOW-TIDAL VOLUME VERSUS JET VENTILATION ON RATES OF FIRST-PASS ISOLATION DURING PULMONARY VEIN ISOLATION
Authors: Juliana Perez Pinzon, Jonathan Waks, Shu Yang, Timothy Maher, Andrew H. Locke, John-Ross D. Clarke, Enrico Giuseppe Ferro, Ronuk Modi, Daniel Bruce Kramer, Peter J. Zimetbaum, Kapil Kumar, Alexei V. Shvilkin, Charles I. Haffajee, Alfred E. Buxton, Gregory F. Michaud, Andre d’Avila, Patricia Tung
Journal: Journal of the American College of Cardiology (2025)
MULTI-METRIC RISK SCORE WITH QUANTITATIVE LATE GADOLINIUM ENHANCEMENT PREDICTS SUDDEN DEATH RISK IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
Authors: Raymond H. Chan, Ali Sakhnini, ali pedarzadeh, Ethan Rowin, Manhal Habib, Deacon Lee, Arnon Adler, Barry J. Maron, Harry Rakowski, Martin S. Maron
Journal: Journal of the American College of Cardiology (2025)
ASSOCIATION OF RURALITY WITH MEDICAL PROCEDURES AND MORTALITY IN ATRIAL FIBRILLATION HOSPITALIZATIONS
Authors: Anu R. Twayana, Godfrey Tabowei, Omer Farooq, Izage Kianifar, John Garza, Asley Sanchez, Ibrahim Kamel, Siddharth Bajaj, Laura M. Gonzalez, Biyas Thapa
Journal: Journal of the American College of Cardiology (2025)
Cancer-Associated Venous Thromboembolism — Beyond 6 Months
Authors: Simon Noble
Journal: New England Journal of Medicine (2025)

Venous thromboembolism is a common complication of cancer and its treatments, and the incidence of recurrent thrombosis, serious bleeding, and death is higher among patients with this condition than in the general population. More than 20 years have passed since Lee et al.1 reported the results of the landmark CLOT trial in the Journal. This trial showed the superior efficacy of dalteparin over vitamin K antagonists in the prevention of recurrent venous thrombosis in patients with cancer, and it established a 6-month course of weight-adjusted low-molecular-weight heparin as standard care for cancer-associated thrombosis. Much has changed since the CLOT trial. . . .
CLO25-067: Risk of Trastuzumab Deruxtecan (T-DXd) Associated Interstitial Lung Disease (ILD)/Pneumonitis: A Real-World Population-Based Propensity-Matched Analysis
Authors: Parth Sharma, Piyush Nathani, Rohit Nathani, Anuj Shrestha
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-067: Risk of Trastuzumab Deruxtecan (T-DXd) Associated Interstitial Lung Disease (ILD)/Pneumonitis: A Real-World Population-Based Propensity-Matched Analysis" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-082: Predictors of Survival in Breast Cancer With Brain Metastases: A Multi-Center Institutional Experience
Authors: Rami Tfayli, Ali Hijazi, Mohamed Mohanna, Kaylee Sarna, Saad Sabbagh, María Herrán, Saffett Güleryüz, Razan Mohanna, Rashid Mahrous, Surabhi Ranjan, Zeina Nahleh
Journal: Journal of the National Comprehensive Cancer Network (2025)
HSR25-156: Myelosuppression and Healthcare Resource Utilization in Community Oncology Patients With Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy With or Without Trilaciclib
Authors: Ajeet Gajra, Peter Reeves, Susan O'Brien, Anna Carey, Michelle Moore, Huan Huang
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-156: Myelosuppression and Healthcare Resource Utilization in Community Oncology Patients With Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy With or Without Trilaciclib" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials
Authors: Daniel Thomas Jones, Abbas Hussain, Hazem Aboaid, Riccesha Hattin, Savannah Schauer, Tal Schlesinger, Rory Twells, Karl Aharonian, Ryan Parto, Rodd Rahmani, Chalette Lambert-Swainston, Ramaditya Srinivasmurthy, Kyaw Zin Thein
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-083: Immune-Related Adverse Events in Women With Early and Advanced Triple-Negative Breast Cancer Treated With Pembrolizumab: A Multi-Center Analysis
Authors: Maria Herran, Ahmad Alhalabi, Kaylee Sarna, Theresa Abdo, Rami Tfayli, Zeina Nahleh
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-083: Immune-Related Adverse Events in Women With Early and Advanced Triple-Negative Breast Cancer Treated With Pembrolizumab: A Multi-Center Analysis" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-167: Real-World Study Demonstrates Lack of Biomarker-driven Care in First-Line Treatment for Advanced/Metastatic Non-Small Cell Lung Cancer That Received Next-Generation Sequencing Testing
Authors: Melina E. Marmarelis, Adrienne M. Gilligan, Tomoko Sugihara, Shen Zheng, Tyler Marquart, Sam Whipple, Naleen Raj Bhandari, Charu Aggarwal
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-167: Real-World Study Demonstrates Lack of Biomarker-driven Care in First-Line Treatment for Advanced/Metastatic Non-Small Cell Lung Cancer That Received Next-Generation Sequencing Testing" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-188: Comparative Risk of Acute Kidney Injury Among Cancer Patients Treated With Immunotherapy Using Large-Scale US Clinical Data
Authors: Alex Jiro Carsel, Arash Rashidi, Jaime Abraham Perez, Elleson Harper, Qian Wang
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-188: Comparative Risk of Acute Kidney Injury Among Cancer Patients Treated With Immunotherapy Using Large-Scale US Clinical Data" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin
Authors: Riccesha Hattin, Hazem Aboaid, Abbas Hussain, Savannah Schauer, Tal Schlesinger, Rory Twells, Karl Aharonian, Ryan Parto, Rodd Rahmani, Chalette Lambert-Swainston, Daniel Thomas Jones, Ramaditya Srinivasmurthy, Kyaw Zin Thein, Thura Win Htut
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study
Authors: Kathryn E. Flynn, Joan Clements, Karen DeMairo, Jennifer Hiller, David Wei, Nisha C. Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Kejal Jadhav, Gabriel Marquez, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guérin, Kelly Schoenbeck
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Nasal production of IL-26 involving T cells in smokers with and without COPD
Authors: Julia Arebro, Nikolaos Pournaras, Patricia Ramos-Ramírez, Eduardo I Cardenas, Elga Bandeira, Karlhans Fru Che, Bettina Brundin, Apostolos Bossios, Reza Karimi, Sven Nyrén, Pär Stjärne, Magnus Sköld, Anders Lindén
Journal: Journal of Allergy and Clinical Immunology (2025)
Exploring the Black Box: What Happens During Brief Concentrated Exposure and Response Prevention for Obsessive-Compulsive Disorder?
Authors: Franziska Miegel, Jakob Scheunemann, Saskia Pampuch, Josephine Schultz, Bjarne Hansen, Kristen Hagen, Jürgen Gallinat, Antonia Zapf, Amir H. Yassari, Lena Jelinek
Journal: Psychotherapy and Psychosomatics (2025)

Brief concentrated exposure and response prevention (cERP) has shown promise as an efficacious treatment for obsessive-compulsive disorder (OCD). with higher response and remission rates compared to the first-line treatment. However, the mechanisms driving this success remain unclear. This longitudinal study included 56 patients with OCD who underwent cERP (Bergen four-day treatment; B4DT). Treatment mechanisms (e.g., willingness to engage in ERP, confidence in future self-guided ERP, leaning into anxiety) were assessed before and after each of the four treatment days by the Pre- and Post-Session Questionnaire (PPSQ-cERP). Changes in the PPSQ-cERP were used to predict treatment response assessed from baseline to post-treatment and three-month follow-up. All variables assessed by the PPSQ-cERP showed improvement throughout the cERP, as calculated using linear mixed models. Several variables, including willingness to engage in ERP and self-efficacy, improved after day 3, with small to medium effects (0.34-0.70). Confidence in future self-guided ERP improved on day 4 (the day on which it was addressed), with a small effect (0.31). Leaning into anxiety during ERP tasks on day 3 was identified as a predictor of OCD symptom improvement ( = 0.516, p = .050) by lasso regression, while group cohesion reached trend level ( = 0.239, p = .081). This study highlights day-specific effects across all treatment mechanism variables. Notably, leaning into anxiety during ERP tasks was a key predictor of symptom improvement, offering new insights into refining OCD treatment strategies and enhancing clinical outcomes.
COMPARISON OF IN-HOSPITAL OUTCOMES BETWEEN ISCHEMIC AND NON-ISCHEMIC CARDIOMYOPATHY AMONG PATIENTS ADMITTED WITH VENTRICULAR ARRHYTHMIAS: A NATIONWIDE ANALYSIS
Authors: Amir Joshi, MRIDU UPRETY, Warren Fernandes, Kannu Bansal, Kedar Mahagaokar, Mark Jonathan Kranis
Journal: Journal of the American College of Cardiology (2025)
ATRIAL FIBRILLATION ABLATION IN HEART FAILURE: 1-YEAR OUTCOMES BETWEEN REDUCED AND PRESERVED EJECTION FRACTION
Authors: Aravinthan Vignarajah, Min Choon Tan, Kamala P. Tamirisa, Andrea M. Russo, Justin Zon-Ern Lee, Luis R.P. Scott, Dan Sorajja
Journal: Journal of the American College of Cardiology (2025)
AGE AND SEX DIFFERENCES IN LEFT ATRIAL EPICARDIAL ADIPOSE TISSUE IN PATIENTS WITH ATRIAL FIBRILLATION
Authors: Romanos Haykal, Ahmad Kassar, Nadia Chamoun, Yaacoub Chahine, Hala Al yasiri, Tori Hensley, Nazem Akoum
Journal: Journal of the American College of Cardiology (2025)
INCIDENCE AND OUTCOMES OF CARDIAC DYSAUTONOMIA AFTER BARIATRIC SURGERY: EARLY INSIGHTS FROM THE ADIPOSE REGISTRY
Authors: Eli Herink, Aashish Katapadi, Douglas Darden, Naga Venkata K. Pothineni, Rajesh Kabra, Rakesh Gopinathannair, Donita Atkins, Dhanunjaya R. Lakkireddy
Journal: Journal of the American College of Cardiology (2025)